Key Highlights

• SGT-003 has been generally well tolerated in 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of November 3, 2026

• A Type C meeting with the FDA is scheduled for late Q4 2026 to discuss a potential Accelerated Approval pathway for SGT-003

• Five participants have been dosed in the Phase 1b FALCON trial evaluating SGT-212 for Friedreich's ataxia

• Cash, cash equivalents, and available-for-sale securities totaled $348.9 million as of September 30, 2026, with runway anticipated into H1 2028

Solid Biosciences Inc.(NASDAQ:SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, reported financial results for the third quarter ended September 30, 2026, alongside updates on its clinical programs targeting Duchenne muscular dystrophy and Friedreich's ataxia.

INSPIRE DUCHENNE Trial Progress

The company's lead program, SGT-003, is a next-generation gene therapy candidate for Duchenne muscular dystrophy. As of November 3, 2026, SGT-003 had been dosed in 53 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial. The company reported that SGT-003 has been generally well tolerated across all participants, with the safety profile achieved using a low-burden, steroid-only immunomodulation regimen.

A critical near-term catalyst for the program is a Type C meeting with the FDA scheduled for late Q4 2026. The purpose of the meeting is to discuss the preliminary INSPIRE DUCHENNE data package and seek guidance on a potential accelerated approval pathway for SGT-003. An accelerated approval pathway, if pursued by the FDA, would allow the drug to reach patients earlier based on surrogate endpoints, with post-marketing confirmatory studies required.

Separately, the Phase 3 IMPACT DUCHENNE trial, a placebo-controlled, randomized, double-blind study, commenced dosing in Q2 2026. Participant screening and enrollment remain ongoing for this registrational trial.

Friedreich's Ataxia Program Advances

Beyond Duchenne, Solid Biosciences is advancing SGT-212 for Friedreich's ataxia, a progressive neurodegenerative disease in which cardiac disease remains the leading cause of mortality. Five participants had been dosed in the Phase 1b FALCON clinical trial as of November 3, 2026, and SGT-212 was reported to be well tolerated.

SGT-212 recently received Orphan designation from the European Commission, providing certain development and commercial incentives in Europe. The therapy is designed to address both the cardiac and neurologic manifestations of Friedreich's ataxia through a dual-route administration approach. President and CEO Bo Cumbo noted that the FA patient community has consistently identified slowing neurologic decline as a top priority. Initial data from the FALCON trial is anticipated in the first quarter of 2027.

Financial Position

Solid Biosciences ended the third quarter with $348.9 million in cash, cash equivalents, and available-for-sale securities. The company's cash runway is anticipated to support late-stage development and early pipeline opportunities into the first half of 2028, providing a financial cushion through several anticipated clinical and regulatory milestones.

The cash position reflects the capital-intensive nature of gene therapy development, where Manufacturing costs, clinical trial expenses, and regulatory activities require substantial ongoing investment. The company's ability to fund operations through H1 2028 without additional Capital raises provides a degree of financial visibility for its clinical programs.

The Path Forward

Solid Biosciences sits at a potentially pivotal juncture, with the late Q4 2026 FDA meeting on SGT-003 representing a key inflection point for the company. The outcome of that discussion could define the regulatory pathway and timeline for the Duchenne program. Meanwhile, the FALCON trial for Friedreich's ataxia offers Diversification beyond the company's lead indication, with initial data expected early in 2027.